Experience
Sarepta Therapeutics
Academisch Ziekenhuis Leiden
Successfully represented University of Western Australia in interferences involving eteplirsen.
Sarepta Therapeutics v. Academisch Ziekenhuis Leiden, 106,007, 106,008, 106,013, PTAB
Academisch Ziekenhuis Leiden v. University of Western Australia
University of Western Australia
Academisch Ziekenhuis Leiden v. University of Western Australia
University of Western Australia
Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Nanosys, Inc. v. The Board of Trustees of the University of Arkansas et al.
The Board of Trustees of the University of Arkansas et al.
Robert Bosch GmbH et al.
SAP prevails in first PTAB post-grant review decision
SAP America Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.